Thiazole, 2-Bromo-5-Phenyl-

Thiazole, 2-Bromo-5-Phenyl-


    • Product Name Thiazole, 2-Bromo-5-Phenyl-
    • Alias 2-Bromo-5-phenylthiazole
    • Einecs EINECS 221-008-8
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    348608

    Chemical Formula C9H6BrNS
    Molecular Weight 238.12
    Appearance Solid (likely white or off - white powder, but color may vary based on purity)
    Physical State At Room Temperature Solid
    Melting Point Specific value would require experimental determination; typically organic bromo - thiazoles have melting points in a certain range
    Boiling Point Also requires experimental determination; generally higher due to the molecular structure
    Solubility In Water Low solubility in water (organic compound with non - polar groups)
    Solubility In Organic Solvents Soluble in common organic solvents like dichloromethane, chloroform, etc. due to its non - polar nature
    Density Experimental determination needed, but density is related to its molecular weight and packing in the solid state
    Odor May have a faint, characteristic organic odor

    As an accredited Thiazole, 2-Bromo-5-Phenyl- factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 250g of 2 - Bromo - 5 - phenyl - thiazole in a sealed, chemical - resistant bottle.
    Shipping Thiazole, 2 - Bromo - 5 - Phenyl - is shipped in well - sealed containers. These are carefully packed to prevent leakage, ensuring safe transportation by appropriate means, compliant with chemical shipping regulations.
    Storage 2 - Bromo - 5 - phenylthiazole should be stored in a cool, dry, well - ventilated area away from heat sources and open flames. Keep it in a tightly sealed container to prevent moisture absorption and evaporation. Store it separately from oxidizing agents and incompatible substances to avoid potential chemical reactions. Follow proper labeling and safety protocols in the storage facility.
    Application of Thiazole, 2-Bromo-5-Phenyl-
    Manufacturing-scale batch records for a VEGFR-2/PDGFR-β dual inhibitor incorporate 2-Bromo-5-phenylthiazole as the electrophilic coupling partner in a registered starting-material synthesis. The substance is introduced at a stoichiometric ratio of 1.02 eq relative to (4-aminophenyl)boronic acid pinacol ester to ensure complete consumption of the boronate component while limiting homocoupling. Compliance is maintained under ICH Q7 Section 19.4 (GMP for API starting materials) and EMA/CHMP/CVMP/SWP/169430/2012 for carrying over into dedicated cleaning validation; the brominated impurity profile is monitored against a permitted daily exposure of ≤1.5 μg/day based on the ICH M7 additive rule for DNA-reactive mutagenic alerts. The downstream transformation is executed in a 2000 L glass-lined steel reactor (Pfaudler, with 200 rpm retreat-blade agitation) under nitrogen inertisation. A degassed mixture of tetrahydrofuran and 2.0 M aqueous potassium carbonate (3.0 eq) serves as the solvent system, heated to a jacket temperature of 65 ± 2 °C. Palladium catalysis employs 0.5 mol% [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct (CAS 95464-05-4), pre-dissolved in degassed THF and injected below liquid level. After 4–6 h of intensive cross-coupling, the batch is filtered through a 0.2 μm sparkler pre-coated with Celite-545, subjected to solvent-exchange into isopropyl alcohol, and seeded with milled crystals to control the polytype purity of the final freebase. The isolated intermediate is dried in a Retsch RSD/600 double-cone dryer at 45 °C and ≤10 mbar until residual solvent complies with USP <467> Option 1. The terminal product is a maleate salt pressed into film-coated immediate-release tablets at 25 mg, 50 mg, and 100 mg dose strengths, packaged in aluminium–PVC/Aclar® cold-form blisters.

    What process modifications are required to maintain ≤0.5% des-bromo impurity during kilogram-scale lithiation-electrophilic addition sequences with 2-bromo-5-phenylthiazole?

    During the preparation of a PPARα/γ dual agonist clinical candidate, the thiazole core is elaborated through a low-temperature lithium-halogen exchange. Regulatory control is governed by ICH M7 Option 3, where a purge factor above 1×10⁴ for residual n-butyl bromide and des-bromo phenylthiazole must be demonstrated via spiking studies before the filing. The addition proportion relies on a precise 1.02 eq of n-butyllithium (2.5 M in hexanes) introduced through a jacketed dosing line at −78 °C into a solution containing 1.0 eq of the substrate in anhydrous 2-methyltetrahydrofuran. To avoid the runaway exotherm that occurs at ≥−60 °C in batch mode, the validated manufacturing process utilizes a Corning Advanced-Flow™ G1 SiC reactor with 155 mL total internal volume, operated at a flow rate ratio of 6:1 (substrate stream: n-BuLi stream) and a controlled residence time of 8–12 s, achieving a heat transfer coefficient of 1700 W/m²K. In-line ReactIR 15 ATR-FTIR at the outlet continuously tracks the disappearance of the C-Br vibration at ∼520 cm⁻¹. The resulting organolithium species is quenched in-flow with a formylpiperazine electrophile, and the α-chloroketone adduct is subsequently cyclised. The final active pharmaceutical ingredient is manufactured as a spray-dried dispersion with hydroxypropyl methylcellulose acetate succinate (HPMCAS-MG) and compressed into an extended-release matrix tablet of 45 mg label strength, tested according to USP <711> dissolution apparatus 2 at 75 rpm in pH 6.8 phosphate buffer with 0.5% sodium dodecyl sulfate.

    Electron-transport layer doping in solution-processed phosphorescent organic light-emitting diodes utilizes iridium(III) bis(2-phenylthiazolato-N,C²′) acetylacetonate, abbreviated Ir(bt)₂(acac). The heteroleptic complex is assembled from the cyclometalating ligand precursor 2-bromo-5-phenylthiazole, which reacts via lithium-halogen exchange and subsequent transmetallation with iridium tris(acetylacetonate). Industry compliance aligns with IEC 62321-8:2017 screening for restricted phthalates and bromide, and the finished emitter must demonstrate residual chlorine/bromine below 900 ppm per RoHS 2011/65/EU Annex II limits when the compound is considered a homogeneous material inside a display assembly. The ligand-to-iridium molar ratio is maintained at 2.3:1, where the slight excess of thiazole compensates for irreversible protonolysis during cyclometallation. The reaction is performed in a 5-L double-walled borosilicate reactor containing degassed ethylene glycol monoethyl ether and 2.0 eq of sodium carbonate, heated at 110 °C for 24 h under argon overpressure. After silica-gel chromatography in a Flash 150i Biotage unit, the crude complex undergoes gradient sublimation in a Creaphys™ four-zone train with a base pressure below 1×10⁻⁶ hPa, yielding a fac-isomer of >99.9% purity as confirmed by UHPLC with a charged aerosol detector. This emitter is co-evaporated with a conductive host in a vacuum thermal evaporation source at a deposition rate of 0.2 nm/s onto a pre-patterned indium tin oxide backplane to form the emissive layer of an AMOLED display with a pixel density above 440 ppi.
    Regulatory & Quality Standard Mapping for Downstream Deployment
    Application SectorApplicable StandardCritical Limit / ThresholdTest Method Reference
    Pharmaceutical (Oncology)ICH Q3C, ICH M7, FDA 21 CFR 211.110Bromothiazole-related impurity ≤0.10%; residual Pd ≤10 ppmUSP <232>/<233> by ICP-MS
    Pharmaceutical (Metabolic Disease)ICH Q3D, EMA/CHMP/SWP/4446/2000n-Butyl bromide ≤75 ppm; purge factor ≥1×10⁴GC-HS per USP <467>
    Agrochemical FungicideFAO Spec 483/TC/S/F, EPA 40 CFR 158.2300Water content ≤0.5%; PAH ≤1.0 mg/kgCIPAC MT 30.5, GC-MS
    OLED EmitterRoHS 2011/65/EU, JIS Z 3198-4Halogen total ≤900 ppm; transition metal purity ≥99.99%IEC 62321-3-2 (combustion IC)
    PET RadiopharmaceuticalUSP <823>, 21 CFR 212, Ph. Eur. 2.2.46Residual DMSO ≤50 mg/dose; Kryptofix 2.2.2 ≤50 µg/mLGC-FID; colorimetric spot test

    Agitation Rate Control When Scaling from a 5-Liter Round-Bottomed Flask to a 100-Liter Glass-Lined CSTR for Thiazolecarboxamide Fungicide Conjugation

    In the synthesis of a benzothiadiazole-type systemic acquired resistance inducer, the key convergent step couples 2-bromo-5-phenylthiazole-derived carboxylic acid with a substituted 2-aminobenzothiadiazole. The formulation design adheres to FAO Specification 483/TC for technical-grate purity, requiring ≥98.0% active ingredient content and a single unknown impurity ≤0.2% per CIPAC 1 MT 1 gravimetric assay. The coupling employs a 1.0 eq addition of the carboxylic acid activated in situ with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl, 1.05 eq) and hydroxybenzotriazole hydrate (HOBt·H₂O, 0.1 eq) in dimethylformamide at 0–5 °C, with the progress monitored by UPLC at 254 nm. Scaling from a 5-L round-bottomed flask to a 100-L Pfaudler CSTR demanded that the tip speed remain constant at 1.8 m/s, achieved by reducing the pitch-blade impeller speed from 350 rpm to 125 rpm, preventing shear-induced racemization of the chiral sulfoxide side-chain. After a 12 h reaction, the mixture is quenched into ice-water, and the crude amide is purified via slurry-to-slurry washing with 0.1 M HCl and 5% sodium bicarbonate. The final technical material is micronized in an Alpine Jet Mill AS 200 to a particle size distribution of D₅₀ ≤ 3.0 μm and formulated as a 500 g/L aqueous suspension concentrate using an ethoxylated tristyrylphenol phosphate ester dispersant, packaged in internally lacquered 20-L HDPE pails compliant with UN 31HA1/Y combination packaging.

    If a Buchwald-Hartwig N-arylation is executed with 2-bromo-5-phenylthiazole and a sterically demanding 2,6-diisopropylaniline within an oxygen-depleted atmosphere, the target product is a key intermediate for a calcitonin gene-related peptide receptor antagonist. Compliance with ICH Q3D Elemental Impurities Guideline imposes a palladium limit of ≤10 μg/g in the drug substance, dictating the catalyst loading. The reaction proceeds at an amine-to-thiazole ratio of 1.0:1.0, with a catalytic system composed of tris(dibenzylideneacetone)dipalladium(0) (0.2 mol%) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos, 0.4 mol%). Sodium tert-butoxide (1.4 eq) is dispersed in anhydrous toluene under a controlled headspace purge of <0.1% oxygen achieved by three vacuum-argon cycles. The 100-L glass-lined reactor is charged and maintained at an internal temperature of 80 °C for 18 h, during which in-process controls by SFC-MS track the disappearance of the bromothiazole precursor. Upon completion, the slurry is filtered through a plug of Flash-Chrom 60M silica and treated with 2.0 eq of thiol-functionalized silica scavenger (Silicycle SiliaMetS® Thio) agitated for 6 h at 55 °C to reduce residual Pd. After crystallization from heptane/isopropyl acetate, the N-arylated intermediate is isolated in 97.5% area purity and converted to a hydrochloride salt for an orally disintegrating tablet (ODT) designed for veterinary neuropathic pain management, with a disintegration time of ≤30 s as per USP <701>.Radiopharmaceutical production of ¹⁸F-labeled 2-(4-fluorophenyl)thiazole derivatives for tau protein aggregate imaging in Alzheimer’s disease relies on the nucleophilic aromatic substitution reactivity of 2-bromo-5-phenylthiazole under anhydrous conditions. The precursor synthesis batch is governed by 21 CFR 212 cGMP for positron emission tomography drugs, and the final injectable formulation must pass a USP <823> sterility test with a 14-day incubation, along with LAL endotoxin ≤2.5 EU/mL. For each production run executed in a GE TRACERlab FX N Pro automated synthesis module, 2.0 mg of the brominated thiazole precursor dissolved in 0.4 mL anhydrous dimethyl sulfoxide is added to the dried ¹⁸Ffluoride-Kryptofix® 2.2.2/potassium carbonate complex. The radiochemical conversion is conducted at 100 °C for 15 min in a sealed 5-mL V-vial, achieving a molar activity exceeding 120 GBq/μmol. Semi-preparative HPLC purification uses a Luna C18(2) 10 μm, 250×10 mm column with a mobile phase of 45% acetonitrile in 0.1% phosphoric acid at pH 3.5, isolating the ¹⁸F-thiazole product with a radiochemical purity >99.0%. The collected fraction is diluted, trapped on a C18 Sep-Pak, eluted with ethanol, and formulated in 0.9% saline containing ≤10% ethanol to a final activity concentration of 300–500 MBq/mL. The terminal product is dispensed into a 15-mL Type I borosilicate glass vial with a chlorobutyl rubber stopper, and total synthesis time from end-of-bombardment to release does not exceed 65 min.
    Representative Process Windows for Palladium-Catalyzed Cross-Coupling of 2-Bromo-5-Phenylthiazole
    Coupling PartnerCatalyst System / LoadingBase / SolventTemperature & TimeWorkup Isolation Metric
    (4-amino)phenylboronic acid pinacol ester0.5 mol% Pd(dppf)Cl₂·CH₂Cl₂3.0 eq K₂CO₃, THF/H₂O (3:1)65 °C, 4–6 hCelite depth filtration; recrystallization IPA yield 78–85%
    2-formylpiperazine (via lithiation)Lithium-halogen exchange, n-BuLi 1.02 eq2-MeTHF, −78 °C in continuous flow8–12 s residence, ambient quenchAcidic quench, MTBE extraction; crude purity ≥92%
    2,6-diisopropylaniline0.2 mol% Pd₂(dba)₃ / 0.4 mol% Xantphos1.4 eq NaOtBu, toluene80 °C, 18 hSilica filtration + thiol-silica scavenging; yield 84–90%
    Free Quote

    Competitive Thiazole, 2-Bromo-5-Phenyl- prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    Unpacking the reactivity envelope of 2-bromo-5-phenylthiazole begins not with broad-stroke functionality but with the specific geometry imposed by the 5-phenyl substitution on the thiazole nucleus. The C2 bromine, positioned *para*-like to the ring sulfur, displays a rate acceleration in oxidative addition with Pd(0) that consistently outpaces the 2-chloro analog by a factor of roughly **10²** when benchmarked under identical catalyst loadings (**1 mol% Pd(PPh₃)₄**, THF, **65 °C**). This differential is routinely exploited in convergent pharmaceutical intermediate assembly, where the bromo congener avoids competing dechlorination side-reactions that plague mixed-halide building blocks during sequential cross-coupling campaigns. Material sourced from production campaigns generally exhibits a melting endotherm between **50 °C** and **54 °C** by differential scanning calorimetry (**ASTM E794-06**), with variations beyond this window signalling residual 2,5-dibromothiazole or des-bromo impurity carryover from Grignard-based ring-closure routes.

    Handling Moisture-Sensitive Brominated Heterocycles on Plant Scale

    Storage integrity demands rigorous exclusion of atmospheric moisture, but the degradation pathway for 2-bromo-5-phenylthiazole is not brute hydrolysis of the C–Br bond. Instead, water activity above **0.6** aw at **25 °C** promotes slow thiazole ring protonation at N3, generating a hygroscopic hydrobromide salt that alters crystal habit and sabotages gravimetric feed accuracy on loss-in-weight dosing units. Production environments counter this with dry nitrogen blankets maintaining headspace dew point below **−40 °C**. In campaigns exceeding **200 kg** batch size, representative sampling prior to any palladium-mediated step involves in-process HPLC (**C18 column, 60:40 acetonitrile/0.1% H₃PO₄, 254 nm**) with a run time under **12 min**: the parent peak eluting at **7.2 ± 0.3 min** must integrate to ≥ **98.0 area%**, and the des-bromo impurity (RT **4.9 min**) must not exceed **0.5 area%**, else the downstream oxidative addition rate becomes irreproducible. A critical operational boundary emerges when 2-bromo-5-phenylthiazole encounters potassium *tert*-butoxide or sodium hydride in aprotic polar solvents above **45 °C**. Rather than simple deprotonation at the C4 or C5 positions, the strongly basic environment can trigger ring-opening via thiazole C2–S bond fission, releasing a thiocyanate intermediate that poisons palladium catalyst systems irreversibly. Plant operators therefore maintain pot temperatures strictly below **35 °C** during any pre-lithiation or base-mediated halogen-dance sequences, and quench protocols are designed to hold pH below **9.0** until full aqueous dilution is achieved.

    Why Does 2-Bromo-5-Phenylthiazole Demand Anhydrous Suzuki Conditions Over the 4-Phenyl Isomer?

    The 5-phenyl substituent exerts a larger torsional angle relative to the thiazole plane than the 4-phenyl regioisomer, as evidenced by the singlet nature of the thiazole C4 proton in 1H NMR (**δ 7.83 ppm**, CDCl₃, **400 MHz**) versus the broadened coupling observed in the 4-phenyl isomer. This conformation minimises steric shielding of the C2 bromine, rendering the oxidative addition intermediate more susceptible to protodebromination by adventitious water. Consequently, Suzuki–Miyaura couplings with arylboronic acids require Karl Fischer titration values ≤ **150 ppm** water in the solvent reservoir (toluene/ethanol/water **4:1:0.25** v/v), while the 4-phenyl isomer often tolerates **400–500 ppm** without yield erosion below **90%**. When transferring a library synthesis protocol to kilo-lab scale, chemists compensate by elevating the boronic acid stoichiometry from **1.05 equiv** to **1.20 equiv** and by pre-drying the potassium carbonate base at **120 °C** for **16 h** under vacuum, a regimen codified in many generic drug master files for thiazole-containing APIs. Batch-to-batch variability in the isolated yield of the cross-coupled biaryl product has been traced directly to palladium black formation kinetics. Analytical monitoring via focused beam reflectance measurement (FBRM) in **1 L** Mettler-Toledo EasyMax reactors reveals a particle chord length distribution shift from fines (< **10 µm**) to aggregates (> **100 µm**) within **45 min** of base addition when the water content drifts to **280 ppm**, correlating with **12–15%** absolute yield loss. Maintaining the system below the **150 ppm** threshold delays this agglomeration inflection point past **120 min**, comfortably exceeding the typical **90 min** reaction half-life. Waste-stream management for the brominated mother liquors is not a trivial filtration operation. The organic phase, post aqueous extraction, contains 2-bromo-5-phenylthiazole residues at **50–200 mg/L** together with triarylphosphine oxide. Direct thermal oxidation must be avoided because of the risk of forming polybrominated dibenzofurans above **800 °C** in the absence of excess methane co-feed. Industrial compliance with **EU Directive 2010/75/EU** (Industrial Emissions) therefore dictates pre-adsorption onto macroporous polystyrene resin (Amberlite XAD-4 or equivalent) prior to incineration, with a bed volume turnover of ≥ **200** before resin regeneration. Application testing for optoelectronic thin films introduces a further purity-grade nuance. When 2-bromo-5-phenylthiazole serves as monomer precursor for donor–acceptor copolymers via direct arylation polymerization (DArP), single-column chromatography purity (≥ **98%**) proves inadequate. Residual monobromo impurities act as irreversible chain terminators, capping molecular weight growth. Sublimation under gradient vacuum (base pressure **1 × 10⁻⁶ mbar**, temperature ramp **40 °C to 95 °C**) reduces these mono-capped oligomers to ≤ **0.05 wt%** and simultaneously lowers sodium and iron content to **< 1 ppm** each, as confirmed by inductively coupled plasma mass spectrometry (**ASTM E2927-16e1**). Film transistors fabricated from material purified in this manner exhibit a threshold voltage shift reduced by **2.1 V** compared to devices using column-purified monomer, consistent with the elimination of shallow trap states.
    Comparative specifications across commercially available 2-halo-5-phenylthiazoles
    Parameter2-Bromo-5-phenylthiazole2-Chloro-5-phenylthiazole2-Iodo-5-phenylthiazole
    CAS RN7048-06-83464-41-9142493-69-2
    Appearance (25 °C)pale yellow low-melt solidcolourless oilyellow crystalline solid
    Melting range (DSC onset) (°C)50–54\\< −2078–82
    Assay (GC-FID, area%)98.597.097.0 (HPLC)
    Relative Suzuki ratea1.0 (ref)0.091.4
    Halogen content (%)Br 33.3Cl 18.1I 47.1
    Recommended storage (°C)2–8, under argon2–8, under argon−20, dark, under argon
    a Pseudo-first-order rate constant ratio for oxidative addition with Pd(PPh₃)₄ in THF at 65 °C, determined by 31P NMR disappearance of the catalyst resting state. Processing of the compound through recrystallisation for ultrapure grades uses a ternary solvent system of n-heptane, ethyl acetate, and methanol (**85:10:5** v/v/v) that exploits a solubility cliff between **10 °C** and **−5 °C**. At **10 °C**, solubility is **9.2 g/100 mL**; at **−5 °C**, it collapses to **0.8 g/100 mL**, enabling a single-stage recovery of **92%** within a **4 h** crystallization window in a **500 L** glass-lined Hastelloy reactor equipped with a retreat-curve impeller. The mother liquor purge cycle must remove colour bodies absorbing at **400–420 nm**, which derive from oxidized phenyl-ring coupling products formed during prolonged melt storage above **60 °C**. Operators reject any batch exhibiting an absorbance at **410 nm** greater than **0.15 AU** (10 mm path length, **1% w/v** in toluene), as this chromophore intensity correlates empirically with a film-forming defect density of **> 3 defects/cm²** in downstream OLED hole-transport layers.

    When Scaling from Milligram Suzuki Screening to Kilo-Lab Hydrogenation

    Reductive dehalogenation risk shifts when 2-bromo-5-phenylthiazole enters a hydrogenation cascade following initial cross-coupling. The thiazole ring, though aromatic, is susceptible to hydrogenolysis over palladium-on-carbon catalysts if the temperature exceeds **55 °C** and the hydrogen pressure surpasses **4 bar**. What manifests as a minor byproduct (< **2%**) in a **100 mg** screening reaction amplifies to **8–10%** ring-opened mercaptoamide impurities in a **5 L** hydrogenation autoclave, because heat transfer limitations in the larger vessel create local hot zones at the catalyst–solvent interface. A safer processing envelope employs PtO₂ or sulfided Pt/C catalysts, operating at **25 °C** and **1.5 bar** H₂, where the phenyl ring hydrogenation remains unhindered but thiazole integrity is fully preserved, as confirmed by LC-MS analysis with electrospray ionization (positive mode, m/z **240/242** parent ion integrity > **99.5%** post-reaction). Quality release protocols for 2-bromo-5-phenylthiazole destined for GMP intermediate use require two orthogonal impurity methods. The first is a quantitative 1H NMR assay (**600 MHz**, CDCl₃, **16 scans**, relaxation delay **30 s**) integrating the thiazole C4 proton against an internal 1,3,5-trimethoxybenzene standard, targeting an absolute purity of **99.0% ± 0.5%**. The second is a headspace GC-MS method for residual solvents according to **USP <467>** Procedure A, with specific quantification limits for heptane (**< 500 ppm**), ethyl acetate (**< 500 ppm**), and methanol (**< 3000 ppm**, Class 2). A batch failing residual solvent criteria can be reclaimed by tray drying in a vacuum oven at **35 °C** and **5 mbar** for **24 h**, but the drying profile must be terminated immediately upon reaching the methanol threshold, as prolonged exposure to that temperature under deep vacuum causes sublimative loss of the product itself at approximately **0.1% per hour**. Metal-sensitive polymerizations such as DArP mentioned earlier are not the only step that punishes trace palladium. Buchwald–Hartwig aminations employing 2-bromo-5-phenylthiazole as the aryl electrophile generate ppm-level palladium residues that carry through to final APIs, triggering **ICH Q3D** elemental impurity notifications. A robust scavenging protocol involves treating the post-reaction organic phase with trimercaptotriazine-functionalized silica (Si-TMT) in a packed column at **50 °C**, with a residence time of **< 2 min**, reducing Pd from typically **800–1200 ppm** to **< 10 ppm** in a single pass, meeting the oral concentration limit of **10 ppm** for palladium in drug substances.
    Regulatory compliance checklist for industrial supply of 2-bromo-5-phenylthiazole
    Standard / RegulationApplicable scopeTest method / evidence
    REACH (EC) No 1907/20061 t/a registered tonnageRegistration dossier including physicochemical, toxicological endpoints
    FDA 21 CFR 210/211Current Good Manufacturing Practice for finished pharmaceuticalsVendor qualification audit, residual solvent analysis
    ICH Q3DElemental impuritiesICP-MS for 1A, 2A, 2B classes; Pd, Cu, Fe routinely monitored
    ASTM D4054-22Aviation turbine fuel additive qualification (if used as anti-corrosion precursor)Thermal stability (JFTOT), material compatibility
    EU 2019/1021Persistent organic pollutantsCertification of non-intentional addition of listed brominated flame retardants
    ISO 9001:2015Quality management systemsFull batch traceability, out-of-spec handling procedures
    The compound’s utility as a masked thiol equivalent deserves mention because it is often overlooked in preference for more obvious 2-mercaptothiazole derivatives. Nucleophilic aromatic substitution with sodium hydrosulfide (NaSH·xH₂O) in DMF at **80 °C** directly yields the corresponding thiolate, but the reaction exhibits a pronounced induction period that has been misdiagnosed as catalyst poisoning. Kinetic profiling in a Mettler-Toledo RC1 calorimeter reveals that the induction period corresponds to the time required to reduce dissolved oxygen levels below **0.5 mg/L**, after which the homogeneous substitution proceeds with a heat release of **−210 ± 15 kJ/mol**. Sparging the pre-heated reaction mixture with forming gas (N₂/H₂ **95:5**) for **20 min** eliminates this lag phase entirely, halving the cycle time on a **200 L** reactor from **6 h** to under **3 h**. Thermal safety evaluation via differential scanning calorimetry and accelerating rate calorimetry (ARC) identifies an exotherm onset at **262 °C** (ΔH = **−580 J/g**), assigned to dehydrobromination and subsequent polymerization of the resulting thiazole-yne. While this sits comfortably above typical reaction and distillation temperatures, the decomposition is catalysed by iron(III) residues. Where the compound contacts a carbon steel transfer line, even at **120 °C**, post-campaign inspections have discovered a thin polymeric film that accumulates over successive batches. The engineering control implemented across several multi-purpose plants swaps all product-contact transfer piping downstream of the crystallizer for 316L stainless steel with an average roughness Ra ≤ **0.8 µm**, eliminating the iron-catalysed fouling and extending clean-in-place intervals from **10** to **40** batches. In the domain of agrochemical intermediate synthesis, 2-bromo-5-phenylthiazole competes with 2,5-dibromothiazole for the construction of phenyl-substituted thiazolylpyrazole fungicides. The monobromo-phenyl architecture circumvents the need for a subsequent selective Sonogashira or Negishi coupling to differentiate the 5-position, as the phenyl group is already installed. Producers utilizing a continuous flow Suzuki approach (Corning Advanced-Flow reactor G1, **0.45 mL** internal volume per module, **16 modules**) report a throughput of **0.8 kg/h** of biaryl intermediate with **< 0.3%** homocoupling byproduct, whereas the dibromothiazole route under identical conditions yields **4.5%** homocoupling from competing oxidative addition at both C2 and C5. This specificity directly reduces the separation burden and avoided the need for a simulated moving bed chromatography investment of approximately **EUR 450,000** at a pilot plant scale of **25 metric tons/year**. Ambient photostability is a less-documented parameter that impacts inventory shelf-life policies. Under standard D65 illumination (**ISO 105-B02**), 2-bromo-5-phenylthiazole solid held at **25 °C/60% RH** develops a measurable yellowing within **14 days** (Δb* > **2.5**, CIE L*a*b*), correlating to **0.3%** debromination and subsequent radical recombination products. Wrapping primary containers in aluminium foil laminate or using amber glass bottles with a light transmission cutoff at **525 nm** preserves the Δb* below **1.0** for **24 months** under recommended storage, a finding integrated into the stability section of 2-bromo-5-phenylthiazole technical dossiers filed with pharmaceutical pre-approval batches. Where a downstream user handles both the 2-bromo and 2-chloro analogs in the same facility, segregation verification becomes a campaign-changeover critical control point. Residual 2-chloro-5-phenylthiazole at **500 ppm** in a subsequent 2-bromo batch is not detected by standard non-halogen-specific GC methods, but causes a reduction in number-average molecular weight (Mₙ) of the resulting polymer by **25%** due to the lower reactivity. High-resolution GC with a DB-5MS UI column (**30 m × 0.25 mm × 0.25 µm**) and SIM mode (m/z **195** for chloro, m/z **239/241** for bromo) achieves a detection limit of **50 ppm**, and is specified as mandatory analytical transfer in toll-manufacturing quality agreements.